| Closed |
S1400I |
Lung-MAP S1400I: Non-Match, Nivolumab + Ipilimumab |
12/18/2015 |
4/23/2018 |
79% |
|
|
| Closed |
S1400K |
Lung-MAP S1400K: c-MET Positive |
2/5/2018 |
12/21/2018 |
64% |
|
|
| Closed |
S1800A |
LUNGMAP S1800A: Non-Match Immunotherapy Combination Sub-Study |
5/17/2019 |
11/16/2020 |
100% |
|
|
| Closed |
S1800D |
LUNGMAP S1800D: Non-match Sub-Study |
2/15/2022 |
3/10/2023 |
17% |
|
|
| Closed |
S1900A |
LUNGMAP S1900A: LOH HIGH and/or BRCA 1/2 mutation - Rucaparib |
1/29/2019 |
|
73% |
|
|
| Closed |
S1900B |
LUNGMAP S1900B: RET Fustion Positive - LOXO-292 |
2/10/2020 |
|
5% |
|
|
| Closed |
S1900C |
LUNGMAP S1900C: STK11 - Talazoparib Plus Avelumab |
1/16/2020 |
12/18/2020 |
100% |
|
|
| Open |
S1900E |
LUNGMAP S1900E: KRAS Targeted Therapy Sub-Study |
4/2/2021 |
|
100% |
|
|
| Open |
LUNGMAP |
LUNGMAP Screening Protocol for NSCLC |
1/28/2019 |
|
|
|
|
| Closed |
SWOG-7963 |
m-AMSA in Melanoma, Myeloma, Lymphoma, Oat Cell Lung Carcinoma and Breast Cancer |
4/20/1979 |
4/5/1982 |
|
|
|
| Closed |
SWOG-8507 |
Maintenance versus no Maintenance BCG Immunotherapy of Superficial Bladder Cancer |
12/20/1985 |
12/15/1988 |
|
|
Published
|
| Closed |
SWOG-9149 |
Malignant Glioma |
5/1/1994 |
2/15/2001 |
89% |
|
Published
|
| Closed |
S0330 |
Malignant Peripheral Nerve Sheath Tumors |
12/15/2003 |
1/15/2006 |
60% |
|
Published
|
| Closed |
S0218 |
Malignant Pleural Mesothelioma |
5/1/2002 |
4/1/2003 |
100% |
|
Published
|
| Closed |
SWOG-8107 |
Management of Disseminated Melanoma, Master Protocol |
5/26/1982 |
11/15/1987 |
|
|
Published
|
| Closed |
S0213 |
Mantle Cell Lymphoma |
10/1/2002 |
9/1/2006 |
100% |
|
Published
|
| Closed |
SWOG-7820 |
Maytansine in Advanced Sarcoma |
9/29/1978 |
10/19/1979 |
|
|
|
| Closed |
SWOG-7805 |
Medroxyprogesterone Acetate (MPA) plus Yoshi 864 in Adult Patients with Adenocarcinoma of the Kidney |
5/17/1978 |
3/4/1980 |
|
|
|
| Closed |
S9626 |
Megestrol acetate (20 mg vs. 40 mg) vs. placebo |
4/15/1998 |
5/1/2000 |
100% |
|
Published
|
| Closed |
SWOG-8312 |
Megestrol Acetate and Aminoglutethimide/ Hydrocortisone In Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer |
5/4/1984 |
11/15/1990 |
96% |
|
Published
|
